SCHEMBL5757286

SCHEMBL5757286

Cc1ccc(C(=O)NCCc2ccc(Cl)cc2Cl)c(=O)n1-c1cccc(C#N)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.48
F10 P00742 1/20 0.45
P2RX7 Q99572 1/20 0.44
CXCR3 P49682 1/20 0.44
CNR2 P34972 1/20 0.44
MAPT P10636 2/20 0.43
TNKS O95271 1/20 0.43
PARP1 P09874 1/20 0.43
NOTUM Q6P988 1/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
SNCA P37840 3/20 0.41
KDM4E B2RXH2 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ELANE P08246 1/20 0.40
MAT2A P31153 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5758054 0.91 MAPT (0.47) CNR1P2RX7CNR2MAPTNOTUM
SCHEMBL5757267 0.91 EPHX2 (0.46) F10P2RX7NOTUMKDM4ENPSR1
SCHEMBL5756759 0.88 CNR1 (0.47) CNR1CNR2MAPTNOTUMKMT2A
SCHEMBL5755743 0.87 RAB9A (0.49) CNR1CNR2NOTUMKMT2AMEN1
SCHEMBL5757736 0.85 NOTUM (0.43) CNR1CNR2PARP1NOTUMKDM4E
SCHEMBL5757801 0.85 ELANE (0.56) CNR1P2RX7CNR2MAPTTNKS
SCHEMBL5756791 0.84 NOTUM (0.43) CNR1CNR2MAPTNOTUMKMT2A
SCHEMBL6219380 0.83 DNMT3A (0.44) CNR1TDP1
SCHEMBL5756977 0.82 TP53 (0.47) CNR1CNR2MAPTNOTUMELANE
SCHEMBL5761223 0.82 ELANE (0.55) CNR1CNR2MAPTNOTUMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 CNR1 2232/4885F10 281/4885P2RX7 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.